Skip to main content

Table 3 Epidemiology of MRONJ

From: Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review

MRONJ-inducing drugs

Prevalence

Incidence

Oral bisphosphonates Intravenous bisphosphonates

<0.001% (0% to 0.04%) 1.0% to 2.3% for 3-year administration

1.04 to 69 per 100,000 patient-years 0 to 12,222 per 100,000 patient-years

Anti-RANKL antibody Osteoporosis Cancer

1.3% to 3.2% for 3-year administration

0 to 30.2 per 100,000 patient-years 0 to 2,316 per 100,000 patient-years

Angiogenic inhibitors

0.3% to 0.4%

Anti-sclerostin antibody

Unknown

Unknown

Anti-TNFα antibody

Anti-CD20 antibody

Other monoclonal antibodies

Tyrosine kinase inhibitors

mTOR inhibitors